Sign In
Buy MRNS
$0.550
+0 (+0%)
At Close: May 09, 2025
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
04:30pm, Tuesday, 08'th Nov 2022 Benzinga
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session.
NanoString Technologies, Inc. (NASDAQ: NSTG) sh
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2022 Earnings Call Transcript
01:32pm, Tuesday, 08'th Nov 2022
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Sasha Damouni Ellis – Vice President-Corporate Affairs and Investor Rel
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
10:15pm, Monday, 07'th Nov 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
01:17pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
7 Sizzling Stocks That Are Oblivious to the Manic Market
02:41pm, Thursday, 20'th Oct 2022
It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out
Marinus Pharmaceuticals: Positive News Flow Of Note
05:03pm, Thursday, 22'nd Sep 2022
Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q2 2022 Results - Earnings Call Transcript
02:12pm, Thursday, 11'th Aug 2022
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Sasha Ellis - VP, Corporate Affairs & IR Scott Braunstein - CEO, President
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
12:55pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
10:32am, Thursday, 11'th Aug 2022
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Assertio (ASRT) Q2 Earnings and Revenues Top Estimates
12:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
11:29am, Friday, 05'th Aug 2022 Zacks Investment Research
ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
03:43pm, Friday, 15'th Jul 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
12:58pm, Friday, 15'th Jul 2022
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
07:30am, Wednesday, 13'th Jul 2022
RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
